MiNA Therapeutics
MiNA Therapeutics develops RNAa genetic medicines restoring normal gene function via innate gene activation and partners with pharmaceutical companies.
- London, GBUnited Kingdom
MiNA Therapeutics develops RNAa genetic medicines restoring normal gene function via innate gene activation and partners with pharmaceutical companies.
minatx.comCrawled Nov 5, 2026
Learn more about the science of RNAa therapeutics that underpins our efforts to transform the treatment of diseases.
MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the appointment of David Blakey Ph.D. as Chief Scientific Officer. Dr. Blakey will lead the Company’s research and development activities. “David brings to MiNA a depth of scientific expertise that will be critical in
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today that the European Patent Office (EPO) has granted a patent in the Corey patent estate (EP Patent Number 2641970). This patent stems from the pioneering RNAa research performed by the Corey lab at the University of Texas S
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and c
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today that it has completed an exclusive license agreement with The Regents of the University of California relating to intellectual property rights developed by the Li lab at UC San Francisco (UCSF). The exclusive license comp
MiNA Therapeutics recruits talent for its growing team and invites inquiries about career opportunities.
MiNA Therapeutics prioritizes patient needs.
Bríd joined MiNA in 2021 and became Chief Scientific Officer in 2025, previously leading lung cancer research at the National Cancer Institute.
Deya Corzo serves as Chief Medical Officer-in-residence at Roivant Sciences, specializing in drug development, clinical genetics, and rare diseases.
Date: 14-16 September 2018 Location: London, United Kingdom
Nagy co-founded MiNA Therapeutics and previously led its R&D, focusing on cancer research and gene therapy for over 30 years.
MiNA works in collaboration with world leading research organisations across academic institutions and industry partners.
MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom
MiNA Therapeutics develops small activating RNA (RNAa) therapeutics to restore or enhance gene function for disease treatment.